Drug Profile

GET 73

Alternative Names: Gamma hydroxybutyric acid analogue; GET-73; GHB analogue

Latest Information Update: 01 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CT Laboratories
Class Anilides; Drug withdrawal therapies; Fluorobenzenes; Hydroxybutyrates; Neuroprotectants; Obesity therapies; Small molecules
Mechanism of Action Metabotropic glutamate receptor 5 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Nov 2022 GET 73 is still in phase I/II trials for Alcoholism in USA NCT04831684
15 Sep 2021 Medical University of South Carolina initiates a phase I/II trial for Alcoholism in USA (PO) (NCT04831684)
05 Apr 2021 Medical University of South Carolina in collaboration with National Institutes of Health (NIH) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) plans a phase I/II trial for Alcoholism (PO) (NCT04831684)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com